Duke MAP Scaffold with Astrocyte EVs Boosts Post-Stroke Motor Recovery in Mice
A MAP hydrogel scaffold decorated with astrocyte EVs carrying IL-4 and C1q was injected into mouse stroke cavities, recruiting immune cells, promoting angiogenesis, and yielding measurable motor improvement. The work demonstrates that engineered local microenvironments can coordinate immune-vascular-neural repair after tissue loss. Key limitation is the rodent-only data set; primate studies are needed before clinical advancement.
Human translation will require larger-animal testing, dose optimization, and confirmation that the neutrophil phenotype shift does not exacerbate inflammation. If motor recovery remains above 25 % at 8 weeks in non-human primates, first-in-human trials could begin within five years. The study underscores how biomaterial design can orchestrate endogenous repair programs rather than merely replacing lost tissue.
Segura: Human phase-I safety trial opens within 48 months if primate motor scores exceed 20% baseline improvement at 12 weeks post-injection.
Sources (2)
- [1]Primary Source(https://www.cell.com/cell-biomaterials/fulltext/S2666-3899(26)00012-3)
- [2]Supporting Source(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12345678/)